TY  - GEN
AB  - Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes acute febrile illness and long-lasting joint and muscle pain. The 2013-2016 CHIKV outbreaks in the Americas is one example of how CHIKV can rapidly spread through areas of CHIKV seronegative individuals and cause widespread severe and debilitating arthritic disease. Since there is no currently available licensed vaccine or antiviral for preventing or treating CHIKV and other alphaviruses, there is urgent need to understand the basic processes of viral replication and viral immunity to develop effective prophylactic and therapeutic treatments. In my dissertation, I describe three different strategies to uncover new aspects of CHIKV biology by testing a small molecule inhibitor, a monoclonal antibody therapy, and a novel T cell vaccine.
AD  - Oregon Health and Science University
AU  - Broeckel, Rebecca
DA  - 2017
DO  - 10.6083/m4bc3z3s
DO  - DOI
ED  - Streblow, Daniel
ED  - Advisor
ID  - 7616
KW  - Alphavirus
KW  - Chikungunya virus
KW  - Vaccines
KW  - Disease Outbreaks
KW  - Antiviral Agents
KW  - Antibodies, Monoclonal
KW  - vaccines antibodies
L1  - https://digitalcollections.ohsu.edu/record/7616/files/Broeckel.Rebecca.2017.pdf
L2  - https://digitalcollections.ohsu.edu/record/7616/files/Broeckel.Rebecca.2017.pdf
L4  - https://digitalcollections.ohsu.edu/record/7616/files/Broeckel.Rebecca.2017.pdf
LK  - https://digitalcollections.ohsu.edu/record/7616/files/Broeckel.Rebecca.2017.pdf
N2  - Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes acute febrile illness and long-lasting joint and muscle pain. The 2013-2016 CHIKV outbreaks in the Americas is one example of how CHIKV can rapidly spread through areas of CHIKV seronegative individuals and cause widespread severe and debilitating arthritic disease. Since there is no currently available licensed vaccine or antiviral for preventing or treating CHIKV and other alphaviruses, there is urgent need to understand the basic processes of viral replication and viral immunity to develop effective prophylactic and therapeutic treatments. In my dissertation, I describe three different strategies to uncover new aspects of CHIKV biology by testing a small molecule inhibitor, a monoclonal antibody therapy, and a novel T cell vaccine.
PB  - Oregon Health and Science University
PY  - 2017
T1  - Discovering new vaccines and therapeutics to treat chikungunya virus infections: characterization of an antiviral, a therapy, and a vaccine
TI  - Discovering new vaccines and therapeutics to treat chikungunya virus infections: characterization of an antiviral, a therapy, and a vaccine
UR  - https://digitalcollections.ohsu.edu/record/7616/files/Broeckel.Rebecca.2017.pdf
Y1  - 2017
ER  -